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ABSTRACT
The ILSI Health and Environmental Sciences Institute (HESI) has developed a framework to support a
transition in the way in which information for chemical risk assessment is obtained and used (RISK21).
The approach is based on detailed problem formulation, where exposure drives the data acquisition pro-
cess in order to enable informed decision-making on human health safety as soon as sufficient evidence
is available. Information is evaluated in a transparent and consistent way with the aim of optimizing
available resources. In the context of risk assessment, cumulative risk assessment (CRA) poses additional
problems and questions that can be addressed using the RISK21 approach. The focus in CRA to date
has generally been on chemicals that have common mechanisms of action. Recently, concern has also
been expressed about chemicals acting on multiple pathways that lead to a common health outcome,
and non-chemical other conditions (non-chemical stressors) that can lead to or modify a common out-
come. Acknowledging that CRAs, as described above, are more conceptually, methodologically and com-
putationally complex than traditional single-stressor risk assessments, RISK21 further developed the
framework for implementation of workable processes and procedures for conducting assessments of
combined effects from exposure to multiple chemicals and non-chemical stressors. As part of the prob-
lem formulation process, this evidence-based framework allows the identification of the circumstances in
which it is appropriate to conduct a CRA for a group of compounds. A tiered approach is then pro-
posed, where additional chemical stressors and/or non-chemical modulating factors (ModFs) are consid-
ered sequentially. Criteria are provided to facilitate the decision on whether or not to include ModFs in
the formal quantitative assessment, with the intention to help focus the use of available resources to
have the greatest potential to protect public health.
Abbreviations: aHI: acute hazard index; ADME: absorption, distribution, metabolism, excretion; AOP:
adverse outcome pathway; CCAG: common chemical assessment group; CCRA: chemical cumulative risk
assessment; CRA: cumulative risk assessment; CRI: Cumulative Risk Index; EFSA: European Food Safety
Authority; HI: hazard index; HESI: Health and Environmental Sciences Institute; IC: index compound; ILSI:
International Life Sciences Institute; MCR: maximum cumulative ratio; MOA: mode of action; ModF: mod-
ulating factor; MOET: combined margin of exposure; IPCS: International Program on Chemical Safety;
NAS: United States National Academy of Sciences; NRC: National Research Council; ModFs: modulating
factors; PF: problem formulation; POD: point of departure; RfP: reference point; RfPI: Reference Point
Index; RISK21: Risk Assessment in the 21st Century; RPF: relative potency factor; TEF: toxicity equivalence
factor; USEPA: United States Environmental Protection Agency; WHO: World Health Organization
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Introduction
Current approaches to cumulative risk assessment (CRA)
The consideration of risks posed by exposures to chemicals is
currently performed largely on an individual chemical basis.
However, risk assessment is evolving to more explicitly
address the complexity deriving from the reality of combined
exposure to multiple chemicals and/or non-chemical stressors
(Meek et al. 2011; Sexton 2012). This broadened scope forces
risk assessors to go beyond basic hazard identification and
characterization, and exposure assessment to consider com-
plex combined exposures to various stressors for which there
may be very little existing information. To date, a single uni-
fied and comprehensive approach has not been realized and
may not be practical, given this complexity. However, the
need for this type of approach to CRA is clear. Currently, the
U.S. Food Quality Protection Act states that the U.S.
Environmental Protection Agency (EPA) shall base risk upon
‘‘available information concerning the cumulative effects on
infants and children of [pesticide] residues and other substan-
ces that have a common mechanism of toxicity’’. Likewise, the
U.S. Superfund Regulation, under the Preliminary Remediation
Goals for Non-carcinogens and the European Union
Regulation (EC) No. 1107/2009 call for cumulative non-cancer
risks to be assessed. In addition, high-level recommendations
such as those of the National Research Council (2009) and EU
DG SANCO (SCCS, SCHER, SCENIHR 2012) have emphasized
inclusion of non-chemical stressors in CRA, while maintaining
a focus on the decision context or problem formulation (NRC
2009) and emphasizing the need for risk assessors to identify
priorities for risk management where co-exposures are
expected (Meek et al. 2011).
The HESI RISK21 project
In 2010, the ILSI Health and Environmental Sciences Institute
(HESI) convened representatives from academia, government
and industry in response to calls from the U.S. National
Academy of Sciences (NAS), Canadian Academies and the
European Union, among others, to implement fundamental
changes to the current unsustainable and inefficient risk
assessment process. CRA was considered one of the top prior-
ities in establishing innovative and transparent approaches to
assessing the safety of chemical exposures.
The RISK21 team identified the following principles as
guides (Embry et al. 2014; Pastoor et al. 2014):
1. Focus on problem formulation;
2. Utilize existing information;
3. Consider exposure early in the risk assessment process;
4. Use a tiered approach for development of data and
decision-making.
Based on these principles, the team then developed a
Roadmap and Matrix as the fundamental concepts for deriv-
ation and display of exposure and toxicity information (Embry
et al. 2014; Pastoor et al. 2014). These principles and the
Matrix underpin the RISK21 approach to CRA.
Current CRA frameworks and approaches
The process of assessing risks from combined exposures has
been described and developed in numerous frameworks and
reports (e.g., USEPA 2007; EFSA 2008; NRC 2009; Meek et al.
2011, 2013; Price et al. 2012; SCCS, SCHER, SCENIHR 2012).
Each provides, to some extent, a conceptual structure for
identifying the fundamental elements and basic principles to
evaluate cumulative risks from a combination of chemical
and, at times, non-chemical stressors through the adoption of
a tiered approach. As these frameworks have developed, it
has become apparent that there are fundamentally two differ-
ent perspectives to approach the conduct of a CRA. In one
case, the objective is the prospective evaluation of potential
health effects associated with a defined set of chemical stres-
sors (stressor-based or prospective CRA), typically, but not
exclusively, driven by and conducted for regulatory purposes,
which focuses on a hypothetical population and exposure.
However, in certain instances, a (sub)population of concern
can be identified based on expected specific environmental
conditions. In the other situation, the trigger for the assess-
ment is the observation of a certain effect in a given popula-
tion, where identification and consideration of all potential
contributors to the observed effect are required (effect-based
or retrospective CRA). A hybrid perspective has recently been
described, where the focus is on identification and evaluation
of vulnerable (at-risk) communities and populations dispropor-
tionately affected by cumulative consequences from exposure
to multiple environmental stressors (Sexton 2015).
Objective
The objective of the cumulative risk component of the
RISK21 multi-sector, international initiative was to develop a
means—quantitative to the extent practical—of assessing
the potential adverse health effects from combined exposure
to multiple chemical and non-chemical stressors. An integral
part of the approach is identifying when a CRA is appropri-
ate and necessary, once both the likelihood of co-exposure
and a common toxicity have been demonstrated or hypothe-
sized. The companion paper (Solomon et al. 2016, this issue)
describes the need to appropriately define the scope and
purpose of the assessment in a problem formulation (PF)
step prior to embarking on any CRA. With this as the foun-
dation, the risk assessment approach proposed is to initially
conduct a ‘‘chemical’’ CRA, involving an identified group of
chemical stressors, i.e., two or more chemicals, followed by
consideration of other chemical and non-chemical stressors,
termed as modulating factors (ModFs, see below and
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Simon et al. 2014) which influence the risk posed by the
chemical stressors. Therefore, evaluations focused only on
non-chemical stressors or single chemicals with or without
ModFs were considered out of scope. By creating manage-
able boundaries for this framework, previous work was
extended and a unified approach developed, enabling inte-
gration of multiple perspectives (e.g., effects-based and stres-
sor-based) within a decision-context. The aim has not been
that of providing a definitive methodology to carry out CRA
for which there is certainly a need (Gallagher et al. 2015).
Rather, we provide an easy-to-follow, visual and transparent
framework for addressing the difficult and complex issue
of CRA.
Terminology and scope
Given the various definitions that have been proposed for
CRA and related terms over the last decade, a brief discussion
on terminology is provided to ensure clarity. Definitions of
CRA are presented in Table 1, which have been proposed by
a number of prominent organizations; these definitions illus-
trate the overlap in concept but the specificity in terminology.
Each definition includes some variation of ‘‘combined risks
from aggregate exposures’’ from ‘‘agents or stressors’’. For the
purposes of this RISK21 framework, this terminology was
viewed as too broad and unsuitable within the context of the
HESI RISK21 project, i.e., assessing the adverse health effects
from combined exposure to multiple chemical and non-chem-
ical stressors. A narrower definition is proposed to clarify the
boundaries within which the framework applies.
A chemical CRA (CCRA) is defined as an appraisal—quantitative to
the extent practical—of the adverse health effects from combined
exposure to multiple chemical stressors and all relevant chemical
or non-chemical ModFs (see below).
In addition, the NRC (2009) report and others (Sexton 2012,
2015; Gallagher et al. 2015) propose incorporation of the con-
cepts and factors of vulnerability, susceptibility and sensitivity1
into CRA. Indeed, the NRC does not consider that a CRA is
completed until such factors are considered and quantitatively
incorporated into the assessment. RISK21 recognizes that
these factors need to be addressed and suggests that they
can be broken down into their simple elementary constitu-
ents. Therefore, the term ‘‘modulating factor’’ (ModF),
adapted from the RISK21 companion paper on quantitative
key events/dose–response framework (Q-KEDRF) (Simon et al.
2014), is introduced where individual non-chemical contribu-
tory factors are listed and, when combined, may collectively
comprise the determinants of susceptibility and/or vulnerabil-
ity. While it is recognized that the latter terms are widely
used and concisely convey the message, their use is not rec-
ommended in CRA. In fact, ‘‘quantification’’ of the overall
impact of non-chemical stressors on modifying the response
is much simpler when individual factors are addressed separ-
ately. Alternatively, the resulting combined effects can be
expressed as a single ‘‘value’’ for susceptibility and for vulner-
ability. However, it should be clearly explained that this
‘‘value’’ is the result of combining different factors for which
evidence is provided.
ModFs represent biological, environmental and individual
factors, including control mechanisms or host factors and
other chemicals, that can modulate the response to an identi-
fied (group of) chemical stressor(s) thus altering the probabil-
ity or magnitude of the adverse outcome. ModFs fall into four
main categories including: host factors, lifestyle, environment
and other chemicals. The latter are chemicals that do not
share the mode of action (MOA) or toxicological endpoint
(i.e.: belong to the same cumulative assessment group) but
modify the effect by e.g., interfering with the toxicokinetics of
one or more of the chemicals in the initially considered chem-
icals in cumulative assessment group. Categorization of poten-
tial ModFs is discussed in the companion paper (Solomon
et al. 2016, this issue). It should be noted that this list is not
meant to be exhaustive, not least because some ModFs can
apply to very specific situations (see e.g., DeFur et al. 2007;
NAS/NRC 2009; Sacks et al. 2011; Gallagher et al. 2015).
Within this context both chemicals and the traditionally
termed ‘‘non-chemical stressors’’ can modulate a response to
Table 1. Definitions of CRA.
Organization Year Definition
US Environmental Protection Agency
(Framework for CRA)
2003 Cumulative risk: the combined risks from aggregate exposures to multiple agents or stressors.
CRA: an analysis, characterization and possible quantification of the combined risks to health or the
environment from multiple agents or stressors.
US Environmental Protection Agency (Food
Quality Protection Act)
1996 Cumulative risk: the risk of a common toxic effect associated with concurrent exposure by all relevant
pathways and routes of exposure to a group of chemicals that share a common mechanism of
toxicity.
California Environmental Protection Agency 2005 Cumulative impact: exposures, public health or environmental effects from the combined emissions
and discharges in a geographic area, including environmental pollution from all sources, whether
single or multi-media, routinely, accidentally or otherwise released. Impacts will take into account
sensitive populations and socio-economic factors, where applicable and to the extent data are
available.
National Research Council of the National
Academies
2009 The combination of risks posed by aggregate exposure to multiple agents or stressors in which aggre-
gate exposure is exposure by all routes and pathways and from all sources of each given agent or
stressor.
European Food Safety Authority (PPR Panel) 2009, 2013 Combined risk assessment to exposures from pesticide residues in food that could arise from plant
protection products for the setting of Maximum Residue Limits.
European Food Safety Authority (Scientific
Committee)
2013 Risk assessment of combined exposure to multiple chemicals
World Health Organization, IPCS 2011 Combined exposure to multiple chemicals
CEFIC-MIAT (Price et al. 2012) 2012 ‘‘Combined exposures’’ defined as a receptor’s exposure (where a receptor could be a person or
another organism) to multiple chemicals that are received from either one or more sources by one
or more routes.
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an individual chemical as well as to a common chemical
assessment group (CCAG) that is defined as follows:
A CCAG is a group of chemicals sharing both evidence for
likelihood of co-exposure within a relevant timeframe AND
evidence for dose-additive response.
These definitions clarify the context of the framework
described herein where multiple chemical stressors serve as
the starting point, and chemical and non-chemical ModFs are
subsequently considered as necessary. This approach is most
appropriate for any organization or body dealing with chemi-
cals. However, it can be adapted also for those interested in
personal and life-style factors, provided that there is a way to
quantify the determinants that enter in the risk assessment,
as described below for the ModF. Gallagher et al. (2015), that
summarize EPA efforts in this respect, also indicate that both
increased likelihood of experiencing an adverse outcome or
developing a more severe one, and increased exposures for
geographical and social reasons to stressors should be
considered.
RISK21 cumulative framework approach
This framework builds upon existing knowledge and
approaches, and involves a systematic approach to make the
problem tractable. Furthermore, the approach is based on five
key elements/principles which are also illustrated in Figure 1.
1. A gatekeeper step for determining whether a CRA is
necessary;
2. Problem formulation;
3. Evaluation and collection of toxicity and exposure data in
a tier-wise approach using evidence/concordance tables;
4. Use of the RISK21 Matrix to assess risk
i. Evaluate individual chemicals;
ii. Evaluate cumulative risk;
5. Evaluation of ModFs in a stepwise manner through an
iterative process.
The development of evidence tables facilitates defining
the CCAG. Once the CCAG is determined, cumulative expos-
ure and toxicity are estimated using appropriate methods
and plotted on the RISK21 matrix. If the assessment indicates
that the combined risk to the chemicals is acceptable, then
consideration can be paid to the impact of ModFs. If the risk
is determined not to be acceptable, then a return to the PF
phase at this stage can help refine the assessment, identify
direct information needs or develop a risk mitigation
strategy.
Gatekeeper step
A starting assumption of this framework approach is that
interactions are not likely to occur to a significant extent at
doses/exposure levels of individual chemicals at or below
their no-effect levels, and therefore only dose-additivity would
Figure 1. General conceptual framework of the proposed RISK21 approach to CRA.
Step 1. Preliminary assessment of the need, or lack thereof, to conduct the risk assessment.
Step 2. Problem formulation (PF) (see Solomon et al. 2016, this issue).
Step 3. Detailed evaluation of the data on co-exposure and toxicity on the basis of the PF.
Step 4a. Use of the RISK21 matrix, where individual values are plotted. It is intended that after Mitigation/Refinement (oval in the middle), this step is reiterated.
Step 4b. Plot individual values or IC-normalized values. Refine/Mitigate and reiterate, if needed.
Step 5. Apply appropriate CRA methodology and plot. Refine/Mitigate and reiterate, if needed.
Step 6. Apply ModFs, either to individual compounds or to the IC-normalized values and conclude, either directly or after mitigation, on CRA. Note that, if judged that the margin of exposure
is so high that consideration of ModFs will not significantly change the safety judgment, the calculation of the impact of such ModFs may not be performed and the plot needs not to be re-
drawn, and an appropriate explanation given. All Refinements include, if needed, reiteration of ‘‘gatekeeping’’ and PF.
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be expected for compounds with similar MOA (Boobis et al.
2011; ECETOC 2012). Also, if any single chemical is likely to be
present at doses or concentrations above its health-based
guidance values, such as its reference value, or any other
appropriate value (e.g., TTC for data-poor compounds), it
would be premature to start a CRA until the risk from that
individual chemical had been addressed.
Scientific evidence should be assembled to facilitate a
transparent determination concerning the likelihood of co-
exposure AND the likelihood of common toxicity for all chem-
icals being considered. Both pieces of information are neces-
sary to justify the need to assess cumulative risk and are
emphasized as part of an initial ‘‘gatekeeper’’ step. This step
establishes a minimum set of conditions that trigger the need
for a CRA and requires that sufficient evidence is available to
justify moving into the full PF phase, details of which can be
found in Solomon et al. (2016, this issue).
While the top-down (effects-based) and bottom-up (stres-
sor-based) approaches differ, the ‘‘gatekeeper’’ step can be
adapted to either situations. In the latter case, based on
observed effects in a given population, exposures might be
investigated and the approach is mainly driven by the
observed effect(s). In the former case, compounds are known
(e.g., predefined by a specific regulation or monitoring cam-
paign) and the approach is mainly driven by the measured or
hypothesized exposures.
It is stressed again that, as a first step, each individual
chemical should be evaluated to assess the risk associated
with its estimated/measured exposure. If this is considered
unacceptable, it is not advisable to proceed to any consider-
ation for CRA before taking risk management measures for
that chemical.
A CRA is deemed not necessary or prudent if the totality
of information is such that it does not indicate co-exposure
AND common toxicity (Figure 1). Therefore, the ‘‘gate-
keeper’’ step reinforces the need to assess and utilize all
existing information, i.e., information in-hand, in determining
whether a CRA is necessary or at least should be
considered.
Given a sufficient rationale can be established via available
evidence on likelihood of co-exposure AND common toxicity,
a full PF should ensue (Solomon et al. 2016, this issue). As
shown in Figure 1, the process of CRA does not start if both
exposure and common toxicity do not (likely) occur, i.e., a
‘‘yes’’ from both sides is required to trigger CRA.
It should be noted that this approach could also be
applied to any regulated group of chemicals. Even when
CRA is mandated by an existing regulation, the approach
will indicate where and when the assessment can be ended
because no concern is evident, which does not necessarily
mean that the CRA needs to be conducted up to the high-
est tier. This may seem to contradict the RISK21 approach
(‘exposure first’); however, in this approach, there is already
an exposure consideration (i.e., dietary exposure and all
other exposures for which there is reliable information),
although not refined. In any case, once the initial toxicity
information is available, the next step would be to seek
information on exposure in order to decide if and how to
proceed with the assessment.
Problem formulation
A CRA is ultimately only conducted after following a detailed
PF stage which considers the goals of the risk management,
the purpose of the assessment, the scope and depth of the
analysis, the analytical approach and the resources available
for the assessment (Solomon et al. 2016, this issue). PF is crit-
ical as it clearly identifies the question(s) being asked once a
preliminary determination has been made that a CRA is
necessary. In fact, the PF phase allows further refinement of,
perhaps, the most fundamental question facing risk assessors
and managers during the PF phase: ‘‘In which circumstances
and under what conditions is a CRA necessary or even appro-
priate?’’. In proceeding, the objectives and scope defined by
the PF stage help to focus the risk assessment and potentially
constrain the approach. These include a refinement of the
combination of exposures to the stressors identified at the
gatekeeper step and the use of higher tier information to
exclude some of the initially identified stressors, e.g., from
mechanistic information or more accurate assessment of
exposure.
Evaluation and collection of toxicity and exposure data
in a tier-wise approach using evidence/concordance
tables
After the PF, a concordance table (Table 2) can be popu-
lated with details and refined in a tiered manner. A tiered
approach for CRA has been described by various organiza-
tions, such as WHO/IPCS (Meek et al. 2011). A tiered
approach is also utilized in the RISK21 framework, such that
results obtained from the lower tiers for both toxicity and
exposure can inform the necessary resources required for
the higher tiers and whether this should be for exposure,
toxicity or both. However, the process can be started at any
tier depending on the available information and the needs
of risk management. It is also not necessary to move to a
higher tier if a decision can be made using lower tier infor-
mation (Embry et al. 2014).
Evidence demonstrating co-exposure is based on modeling
or detection in environmental or biological samples and
includes considerations of context and temporality.
Toxicological data may suggest or confirm that dose-additivity
applies, based on QSAR (or other) models, common target
organ, common apical effect, common MOA or adverse out-
come pathway (AOP) or interaction data.
Available evidence for both exposure and ‘‘common’’ tox-
icity in a CCAG will have different strengths and levels of
uncertainty, depending on available data. It should be
noted that both environmental and occupational exposure
can and should be included in the assessment (Williams
et al. 2012; Lentz et al. 2015). Therefore, the definition of a
CCAG may be subject to refinement, based on increasing
exposure and/or toxicological information. However, the
nature and extent of refinement needed will depend on
the outcome of assessments at lower tiers (Gallagher et al.
2015). In certain instances, refinement can be performed by
collection of more information, more sophisticated data ana-
lysis, or modeling; in some cases, it will require additional
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studies. This RISK21 approach, as described for single chem-
icals in Embry et al. (2014), is applicable also in the context
of CRA.
There is currently lack of agreement on the criteria to
determine when it is toxicologically appropriate to include a
chemical in a group for CRA. However, the proposed frame-
work is always applicable, regardless of the criteria used. In
fact, it accommodates groups based on the lowest tier, where
the only criterion for considering substances in the same
CCAG is co-exposure, to subsequent refinements based on in
silico, in vitro or in vivo methods, where evidence for a com-
mon target organ or apical effect serves as the basis for
grouping, or, further, to grouping based on identification of
common mode/mechanism of action or AOP. Similarly, infor-
mation on hazard characterization can be as minimal as the
TTC or as detailed as a dose–response relationship for key
events of a MOA.
Building evidence tables (Table 2) helps to identify those
chemicals which form the CCAG. These tables also present
the strength of evidence or the uncertainty associated with
inclusion of a chemical in the CCAG. In addition, tables also
should be presented for those stressors which are either
included as ModFs (see below) or can be excluded from the
assessment altogether, presenting the considerations and
uncertainties that led to the decision.
Use of the RISK21 matrix to assess risk
CRA methodologies
There are several methodologies that have been proposed to
carry out CRA as summarized in Table 3. Most methodologies
deal simultaneously with toxicity and exposure. For instance,
the HI, CRI, RfPI and the MOET provide a value (adimensional)
that is derived for each component of the CCAG based on
toxicological data and estimated/measured exposure. Usually
these are deterministic point estimates, but they can also be
expressed probabilistically. The TEF/RPF approach, instead,
provides potency values for each component of the group
that are used to ‘‘normalize’’ the dose in relation to the tox-
icity of the ‘‘index compound’’ (IC). Consequently, the expos-
ure to each compound is expressed as equivalents of the IC
and then these can be simply added up and the total IC-
equivalent exposure compared to the toxicity of the IC, as in
a single-chemical assessment.
Plot information on the RISK21 matrix
Given the way the RISK21 matrix is designed, the application
of safety/assessment/uncertainty factors to the Reference
Point (RfP)/Point of Departure (PoD, e.g., NOAEL or BMD) is
not recommended, although it can be done after adjusting
the matrix. Rather the RfP or PoD (single deterministic value,
range, or distribution) and exposure (single deterministic
value, range or distribution) should be plotted on the matrix
as in the ‘‘standard’’ RISK21 approach. Please note that the
TTC values already incorporate a SF of 100; therefore, if plot-
ting both TTCs and specific RfPs on the same matrix, the TTC
values should be multiplied by 100 to enable direct compari-
son. There should be as many dots, clouds or boxes on
the matrix as the number of compounds (see Figure 2). In
Figure 2(A), two lines define three areas: the area of potential
concern for any individual compound (to the right of the solid
line), the area of no concern or irrelevance for CRA (to the left
of the dashed line) and the area in which compounds should
be considered for CRA (between the solid and dashed lines).
In this case, the cutoff for concern for individual compounds
has been set at 1/100th of the RfP, in line with conventional
risk analysis policy (this is analogous to comparing reference
values). The cutoff for the need for inclusion in CRA has been
set at 1/100th of the level of concern for the chemical alone,
i.e., the chemical would add less than 1% to the combined
Table 2. CRA evidence/concordance table (with hypothetical examples included for illustrative purposes).
Evidence to support combined exposure (co-exposure)
Lower tier models Higher tier models Env. monitoring data Biological monitoring
Chemical Description Strength Description Strength Description Strength Description Strength
1 Detected in
groundwater
þþþ
2 Use information &
high solubility
þ Metabolites detected in
urine (human)
þþ
3 Detected in
groundwater
þþ
4 Use indicates leaching to
groundwater at sig-
nificant concentration
þ Metabolites detected in
urine (human)
þþþ
Evidence to support combined toxicity (common toxicity)
Model alerts Common target organ Common apical endpoint Common MOA/AOP
Chemical Description Strength Description Strength Description Strength Description Strength
1 Thyroid follicular cell
tumors
þþ
2 Increased metabolism of
T4 leading to
increased TSH levels
þþ (rat)
3 Thyroid hypertrophy þ
4 Increased metabolism of
T4 leading to
increased TSH levels
þþ (rat)
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effect. However, these cutoff points, i.e., the positions of the
lines, are for illustrative purposes only, and in practice would
be decided in dialog with risk managers and the decision
makers, in a manner consistent with legislative mandates and/
or regulatory policy as documented in the PF. This is consist-
ent with the scheme proposed by Gallagher et al. (2015),
although they propose a specific cutoff for dismissing a chem-
ical from CRA.
The next step depends on decisions made during PF. It
may be that CRA would not be appropriate until the risk of
those chemicals in the area ‘‘potential concern’’ has been
addressed. This could be achieved by the refinement of the
information, either exposure or toxicity, or both, for these
compounds, as described in the conventional RISK21
approach (Embry et al. 2014). If concern still remains for some
or all of these compounds, depending on the PF, it may still
be considered necessary to proceed with CRA for those com-
pounds that fall in the ‘‘between lines’’ area (including any
that were individually of concern prior to refinement). Figure
2(B) represents the situation after such refinement, and the
exclusion of compounds falling into the left-hand area (deep
green). In respect of the latter, this is essentially a different
way of presenting the maximum cumulative ratio (MCR)
approach as proposed by Price and Han (2011), and Price
et al. (2012); this is a tool that helps in the identification of
the compound(s) that drive(s) the risk and those compounds
that can be excluded from further consideration in CRA. The
matrix also provides a graphical representation of a sensitivity
analysis performed to identify the drivers of risk, which is fre-
quently done for pesticide residue risk assessment (see e.g.,
EFSA 2009; USEPA 2002) and see below the worked example
and ensuing considerations. For transparency and communi-
cation purposes the risk assessors might consider to present
both Figure 2(A) and (B) in the final report.
If only nonstandard reference points are available, such as
the LOAEL, consideration should be given as to how these
should be used, if at all; if this are used, the procedure used
to derive an adjusted value for use in the matrix should be
clearly stated (e.g., application of a safety factor of 3 or 10)
and the compounds involved clearly identified in the text and
in the matrix.
In view of the above, the HI/aHI/CRI approach is not
entirely appropriate for the matrix because SFs are applied to
the RfPs before comparison with exposure. However, if this is
known, the decision lines can be adjusted appropriately, as
long as consistent metrics are used for all compounds in the
matrix. Either individual RVs or RfPs can be represented in the
matrix, but the HI/aHI/CRI and RfPI/MOET cannot be repre-
sented directly on the matrix, although this can be repre-
sented as a diagonal line. In contrast, the RPF approach
allows the plotting of individual exposure values, before nor-
malization, as points, ranges or distributions, as well as the
representation of the IC-equivalent as shown in Figure 2(B)
(arrow to star).
Within the RPF approach itself, the level of refinement can
vary, including the distribution of RPFs (if based on BMD), the
RfP of the IC, exposure of each individual compound, or the
combined distribution of IC-normalized exposures.
The TEF approach is used for compounds sharing a MOA,
which are generally present as mixtures, although of variable
composition; the most well-known example being the dioxins
and dioxin-like compounds. With the TEF approach, there will
only be one point (deterministic), a box (range) or a ‘‘cloud’’
(probabilistic) in the matrix since exposure is expressed as the
sum of IC-equivalents, obtained by multiplying the exposure
of each congener.
Consideration of ModFs
Once the assessment has been performed for all components
of the CCAG, if combined exposure is considered not to be of
concern, ModFs should be considered as per goals defined
Table 3. Summary of the characteristics of the commonly used methods to conduct CRA (for more details see e.g., EFSA 2008).
Method Explanation Evaluation Safety/uncertainty/assessment factors
Hazard Index (HI) Sum of the Hazard Quotients (HQ), i.e., the
ratio between exposure and the RV of
each component
HI <1: risk is considered
acceptable
Applied to each component
Adjusted Hazard Index (aHI) Sum of the adjusted HQs, i.e., the ratio
between exposure and the derived refer-
ence value of each component for the
specific effect for CAG. This is applied
when the effect relevant for CAG has a
NOAEL higher than the critical NOAEL
(e.g., that used to set the RV)
aHI <1: risk is considered
acceptable
Applied to each component
Cumulative Risk Index (CRI) Sum of the reciprocals of the HQs CRI >1: risk is considered
acceptable
Applied to each component
Reference Point Index (RfPI) Sum of the ratios of exposure to each com-
pound expressed as a fraction of its
respective RfP for the relevant effect
RfPI <1/SF: risk is considered
acceptable
Applied to the group after all calculations
have been made. Individual RfP can be
‘‘modified’’ by safety factors additional to
the common one prior to calculations.
Combined margin of exposure
(MOET)
Reciprocal of the sum of the reciprocals of
the individual MOEs. Where MOE is the
ratio RfP/exposure
MOET >1 SF: risk is considered
acceptable
Applied to the group after all calculations
have been made. An individual RfP can
be ‘‘modified’’ by safety factors add-
itional to the common one prior to
calculations.
Toxic equivalency/potency equiva-
lency/relative potency factors
(TEF/PEF/RPF)
Normalization of all components to the
potency of an ‘‘index compound’’ (IC).
Exposure expressed as ‘‘IC-equivalents.’’
Calculate HQ for the IC-normalized
exposure.
HQ <1: risk is considered
acceptable
Applied to the IC. Factors that are add-
itional to those of the IC can be applied
to individual components prior to
normalization.
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Figure 2. Application of the RISK21 matrix to a CCAG. In (A), individual compounds are plotted and two lines define three areas: the area of potential concern for any
individual compound (to the right of the solid line), the area of no concern or irrelevance for grouping into a CCAG (to the left of the dashed line) and the area of no
concern for the individual compound that should, however, be considered for CRA (between the solid and dashed lines). The cutoff points, i.e., the position of the lines
have been set in this figure at a ratio toxicity/exposure of 100 for the solid line, 1:10,000 for the dashed line, but these can vary according to the specific situation and
risk management decisions or policy. (B) The refinement obtained by excluding compounds falling into the left-hand area and by gathering additional, more accurate
and refined data, either on exposure or toxicity, or both, for compounds that fall in the ‘‘between lines’’ area, and if appropriate in the ‘‘potential concern’’ area. The
black star and diagonal dotted line represent the sum of the IC-equivalents relative to the IC (arrow) after normalization of the other components of the CCAG.
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during PF. As reported in Simon et al. (2014), ModFs should
be characterized with respect to their effects on biological
processes and key events within a MOA, or on exposure.
While this will not always be applicable because of lack of
specific information, it is proposed that for each ModF identi-
fied as relevant for the CCAG, a table be prepared that sum-
marizes its impact in terms of strength of evidence and
direction of impact, i.e., higher/lower exposure, more/less
severe toxic response, because of e.g., agonism/antagonism,
different levels of endogenous active substances and,
possibly, its (semi)quantitation. In the example presented in
Table 4 (not related to Figure 3) three ModFs for organophos-
phate insecticides (OP) are reported: (1) PON1 polymorphism
(see Simon et al. 2014) which is known to modify metabolism
of an OP in different ways depending on the compound; (2)
A vegetarian diet that increases the intake of residues of OPs;
(3) Exposure to carbamates that also affects acetylcholinester-
ase activity, with a rapid recovery, hence only simultaneous
exposure is relevant.
Unless there is evidence to the contrary (see ModF1 in
Table 4), ModFs can be applied directly to the CCAG as a
whole, via the summed IC-equivalents (Figure 3(A)) or ModFs
can be considered for each individual compound within the
CCAG (Figure 3(B)). ModFs may increase or decrease exposure,
toxicity or both. It is conceivable that certain ModFs affect the
outcome in a different direction and/or to a different extent
for individual compounds as graphically shown in Figure 3(A).
If this is the case, ModFs should be applied to each com-
pound individually. Quantitation of the effects of ModFs may
indicate the possibility of excluding a compound from the
CCAG as it no longer adds significantly to the total risk. On
the other hand, it might be judged that the margin of expos-
ure is so high that consideration of ModFs will not signifi-
cantly change the safety judgment and therefore an
explanation can be provided for not performing the actual
calculation of the impact of such ModFs.
A case study: residues of the triazole fungicides
In an EFSA opinion (EFSA 2009), a CRA case study of triazoles
present as food residues was carried out. Acute (cranio-facial
malformations) and chronic (hepatotoxicity) effects were
addressed and respective two separate CCAGs consequently
formed, based upon each of the two endpoints. It should be
noted that EFSA explicitly stated that this case study was not
a formal risk assessment, that the choice of triazoles was
based on the chemical structure, and that hepatotoxicity was
broadly defined as any effect on the liver. Regarding the latter
point, EFSA recognized that grouping refinement was possible
but that was not the purpose of the exercise as carried out.
On the exposure side, data from supervised field trials and
residue monitoring studies were used. The former included
the Highest Residue (HR) for acute exposure assessment, and
the supervised trials median residue (STMR) for chronic expos-
ure (Table 5). The approach used for assessing combined
effect was that of the RPF and deterministic and probabilistic
exposure assessments were carried out. We present here the
application of the proposed framework to this case study,
where the PF defined the hypothetical assumption that a
registrant has requested approval for marketing of the triazole
bitertanol. Therefore, CRA including all other hepatotoxic tria-
zoles, as necessary, needs to be carried out.
Figure 4(A) plots all the hepatotoxic triazoles using moni-
toring data (see EFSA 2009 for detailed rationale for this)
except for bitertanol where the NOAEL and the highest STMR
(in tomato) were used. According to the criteria described
above, a refinement before carrying out CRA can be done by
excluding the compounds falling to the left of the diagonal
line (note the different position of the line in Figure 4(A) and
(B)). As shown in Figure 4(B) only two compounds remain for
CRA consideration (bitertanol and difenoconazole). When
these are expressed as IC-equivalents (black dot) there
appears to be no concern. Including all of the compounds
that were omitted increases the overall margin of exposure
by only 33%.
The next step would be the consideration of ModFs. In this
case, in order to result in any concern, ModF(s) would need
to increase the response and/or exposure by more than one
order of magnitude, because of the distance of the summed
IC-equivalents from the red line of concern. This situation is
very unlikely to occur given the impact of most ModFs at the
Table 4. Example of ModFs description in a reporting table for organophosphates (OPs). For ModF#1 a separate entry for each com-
pound is needed because ‘‘direction & magnitude’’ differ, while for the others no differences are envisaged.
Impact
Modulation of exposure
or toxicity (EXP/TOX) Description Strength of evidence þ/ Direction & magnitude "#
ModF #1
OP 1 EXP PON1 polymorphism (Q192) þ "
OP 2 EXP PON1 polymorphism (Q192) þ #
OP 3 EXP PON1 polymorphism (Q192) þ "#
. . .. . ..
ModF #2
OP 1 EXP Vegetarian diet þ "
OP 2
OP 3
. . .. . ..
ModF #3. . .
OP 1 TOX Carbamate, simultaneous exposure only þ "
OP 2
OP 3
. . .. . ..
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Figure 3. Application of the RISK21 matrix to the effects of ModFs. In (A), the ModFs are applied to the IC-equivalent because there was no evidence that ModFs were
compound-dependent. The arrows indicate that the shift can be in any direction. (B) can be used when the ModFs are different for each individual compound. In this
example, the RPF should be reassessed and the IC-equivalents recalculated in order to obtain a single combined estimate. Note that the compound indicated with *
can be excluded for further evaluation because its falls into the ‘‘no concern’’ or irrelevance for grouping into a CCAG area.
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levels of exposure occurring as residues in food: in fact, resi-
due levels are unlikely to be significantly modified by process-
ing the food and difference in sensitivity to toxicity to these
compounds well within one order of magnitude. Therefore,
the assessment can be stopped here and there appears to be
no need to refine the exposure assessment for bitertanol by
carrying out monitoring of residues (except for enforcement
purposes).
This short example shows that the framework can be
applied in a regulatory setting and that the use of the matrix
clearly visualizes the process and helps in taking the decision
to the next step. It also shows that preliminary, less sophisti-
cated evaluation could have given the same information in
terms of the ‘‘decision’’ to be taken.
Table 5. Hepatotoxic triazoles. The toxicity data are the respective NOAELs for
hepatotoxicity. The exposure data are from monitoring data, except for biterta-
nol for which the highest supervised trial median residue (STMR) is plotted.
Chemical name
Exposure point estimate
(mg/kg)
Toxicity point estimate
(mg/kg)
Bitertanol 0.00033 1
Cyproconazole 0.000037 2
Difenoconazole 0.00012 1
Diniconazole 0.000031 5
Epoxiconazole 0.000024 0.8
Flusilazole 0.000038 5
Propiconazole 0.000113 2.6
Myclobutanil 0.000037 39
Tebucomazole 0.000139 16
Triademifon 0.00007 16.4
Triadimenol 0.000135 5
Figure 4. Plots of hepatotoxic triazoles (based on data from Table 5). (A) is a plot of all of the hepatotoxic triazoles. The line represents a margin of 1:10,000. (B) A
refinement of the hepatotoxic triazole group for CRA, by exclusion of compounds falling in the ‘‘no-concern for CRA’’ area (i.e., to the left of the 1:100 line). The black
dot represents the IC-equivalent (cyproconazole) exposure vs the IC NOAEL.
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Conclusions
The proposed framework to address CRA is based on the
concepts described in the previous RISK21 papers where the
roadmap and matrix have been explained in detail
(Embry et al. 2014; Pastoor et al. 2014). It also takes advan-
tage of other technical papers from RISK21, where
approaches to and refinement of exposure (Dellarco et al.
2016) and toxicological (Simon et al. 2014) assessments have
been described. Given the complexity of CRA, it is of utmost
importance to have an efficient gate-keeping step and a
clear PF (Solomon et al. 2016, this issue) to avoid unneces-
sary resource-intensive evaluations. The proposed framework,
with the tables and visualization matrix, enables a transpar-
ent, graphical representation of the process, of its iterations
and of the outcome that will help both the conduct of the
assessment and its communication to both specialists and to
a wider, more general, audience. The importance of stake-
holder involvement and understanding, particularly for CRA,
has been recently stressed (Gallagher et al. 2015), based on
EPA experiences, and the visualization tool proposed by
RISK21 may be helpful.
The effects-based general approach to CRA (also called
top-down approach) and the approach based on stressors
(also called bottom-up approach) can be addressed in a uni-
fied manner by the RISK21 CRA. In fact, gate-keeping and PF
use existing exposure and toxicological information to inform
on the need for a full CRA in either a specific situation (e.g.,
observed effects), or in a less defined setting (e.g., known pos-
sible effects of a given group of compounds). Indeed, the
framework is generally coherent with most regulatory require-
ments, and helps to reduce this complex issue to manageable
dimensions. In certain regulatory domains, CRA is required to
be carried out almost irrespective of a prior evaluation of
exposure (EC 2009). However, the proposed approach will
help in reducing to the minimum the amount of information
and resources needed to reach a safety or risk decision for
exposure to multiple chemicals, by integrating exposure infor-
mation early in the process.
Consistent with the overall RISK21 objectives, no definitive
methods for the definition of CCAGs have been proposed.
Instead, the recommended approach is sufficiently flexible so
as to accommodate future developments in this field. It should
be stressed that the application of the framework enables the
identification of the precision that is needed to take a decision.
In a number of cases, such precision will be provided by very
limited toxicological information and, hence, the use of
broadly defined CCAGs will be sufficient for the purpose, with
no need to devote resources for a more refined process of
inclusion and exclusion of compounds from a CCAG.
The modifying effects of chemicals not directly belonging
to a CCAG and of non-chemical agents or stressors are also
taken into account in a quantitative way, to the extent pos-
sible. These additional factors should be accompanied by
explanatory tables and a graphical representation. Therefore,
even where only qualitative or semiquantitative assessments
are possible, or undertaken, the instruments developed clearly
communicate that these factors have been considered and
integrated in the CRA.
In addition, the matrix and roadmap, as explained in the
previous papers (Embry et al. 2014; Pastoor et al. 2014) can
also be applied to better consider risk-risk tradeoffs, taking
into account possible ‘‘beneficial’’ ModFs. The incorporation of
specific conditions that will ‘‘reduce’’ the magnitude of the
estimated risk may prevent unnecessary and possibly costly
risk management decisions which could serve to divert atten-
tion and effort away from more significant problems impact-
ing public health and/or the environment. The impact of
possible risk management options, such as restrictions on use
in certain scenarios or the suspension of approval of a specific
compound can also be readily visualized in terms of the abso-
lute and relative change in the summed IC-equivalents.
Note
1. There are many definitions of sensitivity, susceptibility and
vulnerability in the literature (among others, Kasperson et al. 1995;
American Lung Association 2001; Kleeberger & Ohtuska 2005; Pope
& Dockery, 2006; DeFur et al., 2007; Porta 2008; NRC 2009; Sacks
et al. 2011). The following definitions proposed by NRC (2009) have
been used in this paper:
Sensitivity: The degree to which the outputs of a quantitative
assessment are affected by changes in selected input parameters or
assumptions.
Susceptibility: The capacity to be affected. Variation in risk reflects
susceptibility. A person can be at greater or lesser risk relative to the
individual in the population who is at median risk because of such
characteristics as age, sex, genetic attributes, socioeconomic status,
prior exposure to harmful agents and stress.
Vulnerability: The intrinsic predisposition of an exposed element
(person, community, population or ecologic entity) to suffer harm
from external stresses and perturbations; it is based on variations in
susceptibility to disease, psychological and social factors, and
adaptive measures to anticipate and reduce future harm, and to
recover from an insult.
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